SkylineDx announces Medicare coverage for its predictive melanoma assay Merlin™ Test

ROTTERDAM, Netherlands and SAN DIEGO, May 25, 2022 /PRNewswire/ — Today, SkylineDx, a leading molecular diagnostics company, announces Medicare coverage for Merlin Test. The local coverage determination was issued under the foundational policy “Melanoma Risk Stratification Molecular…

Click here to view original post